Baseline characteristics and overall glycemic control effects
T2DM, fasting blood glucose
INSULIN RESISTANCE
A total of 1274 T2DM patients from two phase III trials were pooled for this analysis, including 202 in the placebo arm, 248 in the sitagliptin 100 mg arm, 412 in the chiglitazar 32 mg arm, and 412 in the chiglitazar 48 mg arm. Demographic and baseline characteristics were generally comparable between the chiglitazar and control groups (Table Demographic and baseline characteristics in the pooled population.Abbreviations: 2 h‐PPG, 2‐hour‐postprandial glucose; BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment for insulin resistance; TG, triglyceride.Glycemic control in all patients. *